FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms
A phase 2 trial of Azacitidine in advanced solid tumours, run by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., active and no longer recruiting.
Overview
FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms is a phase 2 interventional study registered as NCT06858618 by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., with 47 participants enrolled, started 2023-08-16 and due to reach its primary completion in 2026-12-01. Interventions recorded: FCN-338 + Azacitidine and FCN-338 + erythromycin+ Ara-C.
Similar pages
not linked directly; found by shared links- TrialStudy Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC
Shares Shanghai Fosun Pharmaceutical Industrial Development and the tag pipeline.
- TrialStudy to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
Shares Shanghai Fosun Pharmaceutical Industrial Development and the tag pipeline.
- TrialA Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
Shares Shanghai Fosun Pharmaceutical Industrial Development and the tag pipeline.
- TrialStudy of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Shares Azacitidine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies
Shares Azacitidine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
Shares Azacitidine and the tag pipeline.
- TrialA Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
Shares Azacitidine and the tag pipeline.
- TrialA Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
Shares Azacitidine and the tag pipeline.